evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Saved in:
| Title: | evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. |
|---|---|
| Authors: | Cummings, Jeffrey L.1,2 (AUTHOR) jcummings@cnsinnovations.com, Atri, Alireza3,4,5 (AUTHOR), Feldman, Howard H.6 (AUTHOR), Hansson, Oskar7,8 (AUTHOR), Sano, Mary9 (AUTHOR), Knop, Filip K.10,11,12,13 (AUTHOR), Johannsen, Peter13 (AUTHOR), León, Teresa13 (AUTHOR), Scheltens, Philip14,15 (AUTHOR) |
| Source: | Alzheimer's Research & Therapy. 1/8/2024, Vol. 17 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17589193 |
|---|---|
| DOI: | 10.1186/s13195-024-01666-7 |
